| Size | Price | |
|---|---|---|
| 1mg | ||
| 5mg | ||
| Other Sizes |
| ln Vitro |
After binding to mIGF1R, ganitumab (AMG 479; 0.032-500 nM; 10 minutes; CT26 cells) prevents mIGF1R from being activated by IGF1 and IGF2 [1].
|
|---|---|
| ln Vivo |
In mouse lungs, ganitumab (AMG 479; 1 mg/dose; ip; naïve and tumor-bearing animals) prevents IGF1-induced activation of mIGF1R[1]. Peripheral blood neutrophils are reduced by ganitumab (300 μg/dose; ip; female athymic nude mice)[1]. Ganitumab (300 μg/dose; ip; male athymic nude mice) impairs glucose tolerance and raises serum levels of mGH, mIGF1, and mIGFBP3 in male mice[1].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: CT26 cells Tested Concentrations: 0.032-500 nM Incubation Duration: 10 minutes Experimental Results: Inhibited IGF1-induced autophosphorylation of mIGF1R in CT26 murine colon carcinoma cells in a dose-dependent manner. |
| Animal Protocol |
Animal/Disease Models: Naïve and tumor-bearing mice[1]
Doses: 1 mg/dose Route of Administration: intraperitoneal (ip) injection Experimental Results: Inhibited the IGF1-induced activation of mIGF1R and inhibited 80% tumor growth. Animal/Disease Models: Male athymic nude mice[1] Doses: 300 μg/dose Route of Administration: intraperitoneal (ip) injection, twice per week for a total of five doses Experimental Results: Had Dramatically higher serum glucose levels than hIgG1-pretreated mice. Increased serum levels of mIGF1, mIGFPB3 and mGH. Animal/Disease Models: Female athymic nude mice[1] Doses: 300 μg/dose Route of Administration: intraperitoneal (ip) injection, twice per week for a total of five doses Experimental Results: decreased the number of peripheral neutrophils up to 50% compared with hIgG1 controls. |
| References |
[1]. Moody G, et, al. IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice. J Endocrinol. 2014 Mar 17;221(1):145-55.
|
| CAS # |
905703-97-1
|
|---|---|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
